HC Wainwright

Selected news for the person - HC Wainwright, collected since 11/2017. This person shares healthcare news with Oncology, Bausch Health, Regeneron Pharmaceuticals, BioCryst and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 HC Wainwright Reiterates Buy Rating for Dyadic International (NASDAQ:DYAI) Daily Political HC Wainwright Reiterates Buy Rating for Dyadic International (NASDAQ:DYAI) Posted by Latisha Jones on Jan 12th, 2022 Share on StocktwitsHC Wainwright reissued their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research report sent to investors on Tuesday, TipRanks reports. They currently have a $7.00 target price on the biotechnology company’s stock.Dyadic International stock opened at $4.24 on Tuesday. Dyadic International has a ...
1/12/2022 Dyadic International (NASDAQ:DYAI) Receives Buy Rating from HC Wainwright zolmax.com HC Wainwright reissued their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research note issued to investors on Tuesday morning, TipRanks reports. HC Wainwright currently has a $7.00 target price on the biotechnology company’s stock.NASDAQ DYAI opened at $4.24 on Tuesday. The firm has a fifty day moving average of $4.01. Dyadic International has a 12 month low of $3.15 and a 12 month high ...
1/12/2022 Decibel Therapeutics (NASDAQ:DBTX) Upgraded to Hold at Zacks Investment Research - Ticker Report Ticker Report ... discovering and developing transformative treatments to restore and improve hearing and balance. Decibel Therapeutics is based in BOSTON. “Get Decibel Therapeutics alerts: Other equities research analysts also recently issued reports about the company. HC Wainwright started coverage on Decibel Therapeutics in a report on Monday, November 15th. They issued a buy rating and a $23.00 price objective for the company. SVB Leerink decreased their price objective on Decibel Therapeutics ...
1/11/2022 HC Wainwright Reaffirms “Buy” Rating for Dyadic International (NASDAQ:DYAI) rivertonroll.com Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Tuesday, TipRanks reports. They currently have a $7.00 price objective on the biotechnology company’s stock. HC Wainwright ’s price target indicates a potential upside of 65.09% from the company’s current price.Shares of NASDAQ:DYAI traded up $0.08 during trading on Tuesday, reaching $4.24. 200 ...
1/11/2022 Q4 2022 Earnings Forecast for Exelixis, Inc. Issued By Piper Sandler (NASDAQ:EXEL) zolmax.com ... the quarter, down from their prior forecast of $0.18. Piper Sandler has a “Overweight” rating and a $34.00 price target on the stock.EXEL has been the topic of several other research reports. HC Wainwright dropped their price objective on shares of Exelixis from $65.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, November 3rd. Oppenheimer decreased their target price on ...
1/11/2022 Cardiff Oncology (NASDAQ:CRDF) Rating Increased to Buy at Zacks Investment Research - Transcript Daily transcriptdaily.com ... 5th. They issued an outperform rating for the company. Maxim Group reiterated a buy rating and issued a $24.00 price objective on shares of Cardiff Oncology in a research report on Friday, November 19th. HC Wainwright restated a buy rating and issued a $26.00 target price on shares of Cardiff Oncology in a research note on Thursday, September 9th. Finally, Robert W. Baird started coverage on Cardiff Oncology in a ...
1/11/2022 Zacks Investment Research Downgrades Syros Pharmaceuticals (NASDAQ:SYRS) to Sell zolmax.com ... in a research report on Thursday, September 23rd. JMP Securities reiterated a buy rating and set a $20.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, September 21st. Finally, HC Wainwright restated a buy rating on shares of Syros Pharmaceuticals in a research report on Monday, November 8th.[NASDAQ:SYRS] opened at $3.40 on Friday. The company has a current ratio of 5.13, a quick ...
1/11/2022 Synlogic (NASDAQ:SYBX) Rating Lowered to Hold at Zacks Investment Research rivertonroll.com ... Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. “Several other equities research analysts have also recently issued reports on SYBX. HC Wainwright lowered their price objective on Synlogic from $9.00 to $7.00 and set a buy rating on the stock in a report on Wednesday, October 13th. Oppenheimer upgraded Synlogic from a market perform rating to ...
1/11/2022 Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 21.5% in December com-unik.info ... current year.Several brokerages have commented on ELDN. Zacks Investment Research raised shares of Eledon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 19th. HC Wainwright reduced their price objective on shares of Eledon Pharmaceuticals from $35.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 24th. Finally, SVB Leerink restated ...
1/11/2022 Oncternal Therapeutics (NASDAQ:ONCT) Upgraded by Zacks Investment Research to ‚ÄúHold‚Äù thelincolnianonline.com ... Äôs pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California. ‚ÄúSeparately, HC Wainwright restated a ‚Äúbuy‚Äù rating and set a $9.00 price target on shares of Oncternal Therapeutics in a research report on Tuesday, September 21st. One investment analyst has rated the stock with a hold ...
1/11/2022 Oncternal Therapeutics (NASDAQ:ONCT) Upgraded by Zacks Investment Research to ‚ÄúHold‚Äù com-unik.info ... Äôs pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California. ‚ÄúSeparately, HC Wainwright reiterated a ‚Äúbuy‚Äù rating and issued a $9.00 price objective on shares of Oncternal Therapeutics in a research report on Tuesday, September 21st. One equities research analyst has rated the stock with a ...
1/11/2022 Ayala Pharmaceuticals (NASDAQ:AYLA) Downgraded by Zacks Investment Research to “Hold” - Watch List News watchlistnews.com ... issued research reports about the company. Maxim Group assumed coverage on Ayala Pharmaceuticals in a research report on Monday, December 20th. They issued a buy rating and a $22.00 target price for the company. HC Wainwright assumed coverage on Ayala Pharmaceuticals in a research note on Monday, December 20th. They issued a buy rating and a $18.00 price objective on the stock. TheStreet downgraded Ayala Pharmaceuticals from a c- rating ...
1/11/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Sees Large Drop in Short Interest - The Cerbat Gem thecerbatgem.com ... November 30th total of 230,100 shares. Based on an average daily volume of 82,700 shares, the short-interest ratio is currently 2.3 days. Approximately 2.4% of the company’s shares are short sold.Separately, HC Wainwright raised their price objective on shares of Lantern Pharma from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, November 2nd.Lantern Pharma stock opened at ...
1/11/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Sees Large Drop in Short Interest - Watch List News watchlistnews.com ... November 30th total of 230,100 shares. Based on an average trading volume of 82,700 shares, the short-interest ratio is currently 2.3 days. Approximately 2.4% of the company’s shares are sold short.Separately, HC Wainwright boosted their price target on Lantern Pharma from $32.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, November 2nd.Get Lantern Pharma alerts: A number of institutional ...
1/11/2022 Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Receives $32.59 Consensus PT from Brokerages - Watch List News watchlistnews.com ... Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, November 10th. HC Wainwright cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $32.00 to $38.25 in a research note on Thursday, November ...
1/11/2022 Antares Pharma (NASDAQ:ATRS) Shares Gap Up to $3.49 - Watch List News watchlistnews.com ... 2,371 shares.Several brokerages recently weighed in on ATRS. Zacks Investment Research lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, January 4th. HC Wainwright lowered their price objective on shares of Antares Pharma from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, November 5th. One equities research analyst ...
1/11/2022 Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Zacks Investment Research - Transcript Daily transcriptdaily.com ... and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “Get Aclaris Therapeutics alerts: Several other equities research analysts have also recently issued reports on ACRS. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Aclaris Therapeutics in a report on Monday, December 20th. SVB Leerink reiterated a “buy” rating and issued a $26.00 ...
1/11/2022 Zacks Investment Research Lowers X4 Pharmaceuticals (NASDAQ:XFOR) to Sell - The Cerbat Gem thecerbatgem.com ... The company’s product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. “Separately, HC Wainwright cut their price target on shares of X4 Pharmaceuticals from $21.00 to $11.00 and set a buy rating for the company in a report on Tuesday, December 14th.Shares of X4 Pharmaceuticals stock opened ...
1/11/2022 Infinity Pharmaceuticals (NASDAQ:INFI) Stock Rating Lowered by Zacks Investment Research thelincolnianonline.com ... company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. “Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Infinity Pharmaceuticals in a research report on Monday, December 13th. One investment analyst has rated the stock with a sell ...
1/11/2022 Neurocrine Biosciences’ (NBIX) Buy Rating Reaffirmed at HC Wainwright slatersentinel.com HC Wainwright reiterated their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note issued to investors on Friday, Price Targets.com reports. HC Wainwright currently has a $140.00 price objective on the stock.A number of other brokerages have also recently commented on NBIX. SVB Leerink reiterated a market perform rating on shares of Neurocrine Biosciences in a research note on Monday, October 18th. TheStreet cut shares ...